BACTI-B.ST
Fallen FavouriteBactiguard Holding AB (publ) · Healthcare · Sweden · $56M cap · $9K/day traded
SEK 14.55 -5.5% · close 12 Nov · scored 13 Nov
Score down 1.6 since 12 Nov.
Fallen Favourite: A good business, still expensive, and its momentum is weak.
As of 13 Nov 2026, the MoatMap Score for Bactiguard Holding AB (publ) (BACTI-B.ST) is 31/100, ranked against 25,000+ stocks in 38 markets (Quality 52, Value 33, Momentum 34, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT BACTIGUARD HOLDING AB (PUBL)
Read
Bactiguard Holding AB (publ), a medTech company, provides infection prevention technology and solutions in orthopedics, cardiology, neurology, urology, and vascular access areas.
FINANCIAL SUMMARY (SEK)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 226.7M | 204.0M | 241.7M | 215.9M | -1.6% | 218.0M | 209.5M | 235.9M | 4.5% |
| EPS (SEK) | -1.51 | -3.95 | -0.85 | -0.22 | — | 0.22 | — | — | — |
| Shares | 35.0M | 35.0M | 35.0M | 35.0M | 0.0% | 31.0M | — | — | — |
| Debt | 238.7M | 233.1M | 227.8M | 162.9M | -12.0% | 154.8M | — | — | — |
| Equity | 495.7M | 353.2M | 328.3M | 314.9M | -14.0% | — | — | — | — |
| Op CF | 3.1M | -52.3M | 25.0M | -1.5M | 185.7% | 30.6M | — | — | — |
| Inv CF | -10.9M | -8.6M | -14.8M | -5.7M | — | — | — | — | — |
| Fin CF | -13.9M | -11.8M | -21.2M | -62.7M | — | — | — | — | — |
Made a new 52-week low 4 trading days ago, 33% below its 52-week high. The fall has not stopped yet.
Swung more than 74% of stocks we rank over the past year (volatility 60% a year).
How this is worked out
The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.
- Still falling (this stock): It set a new 52-week low in the last two weeks, after a deep fall.
- Finding a floor: It fell hard, but has set no new low for more than two weeks.
- Turning up: It has climbed off its low and is back above a rising 50-day average.
- In an uptrend: It is near its 52-week high and above its 200-day average.
- No clear trend: None of the above: no recent deep fall and no steady climb.
- No read yet: Not enough price history yet: it needs a year of trading.
In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.
The exact rules
Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BACTI-B.ST are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| BACTI-B.ST | Bactiguard Holding AB (publ)(you) | $56M | 31 |
| SEDANA.ST | Sedana Medical AB (publ) | $97M | 31 |
| DVYSR.ST | Devyser Diagnostics AB (publ) | $87M | 28 |
| SEZI.ST | Senzime AB (publ) | $58M | 14 |
| BICO.ST | BICO Group AB (publ) | $171M | 33 |
| EPIS-B.ST | Episurf Medical AB (publ) | $100M | 10 |
| CRAD-B.ST | C-Rad AB (publ) | $70M | 69 |
| PAX.ST | Paxman AB (publ) | $150M | 56 |
| XVIVO.ST | Xvivo Perfusion AB (publ) | $654M | 36 |
| VITR.ST | Vitrolife AB (publ) | $1.5B | 50 |
Peer medians: ROE 5.4% · P/E 33.9x · Gross margin 67.3%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.